Augmentin – BID 500mg/125mg (Amoxicillin / Clavulanic Acid)

$65.00$85.00

Pack: 10 or 14 tabs (500mg/125mg)
Active Ingredient: Amoxicillin / Clavulanic Acid
ManufacturerGlaxosmithkline

How Many Pills? PriceQuantity
10 Pills $65.00
14 Pills $85.00
  • Description
  • Reviews (0)

Description

Main features of Augmentin – BID 500mg/125mg
Augmentin – BID 500mg/125mg is a pharmaceutical product which combines 2 main components: amoxicillin and clavulanic acid. The final product is an antibiotic which is resistant to a wide variety of microorganisms which develop infections within the body.
Amoxicillin derives from penicillin family of antibiotics. Relying on the fact that penicillins have developed susceptibility to certain pathogenic strains and microorganisms, clavulanic acid is added into Augmentin – BID 500mg/125mg composition. Its role consists in preventing amoxicillin to become susceptible to bacterial action. Clavulanic acid is a beta-lactamase inhibitor, which means that it prevents beta-lactamase enzymes to degrade antibiotic action.

What does Augmentin – BID 500mg/125mg treat?
This antibiotic is efficient for the treatment of a large variety of bacterial infections. It is essential to mention the fact that  Augmentin – BID 500mg/125mg will furnish high effectiveness only in health conditions which are triggered by susceptible bacteria. In this context, culture investigations should be performed before initiating Augmentin – BID 500mg/125mg therapy. In the absence of these findings, patients are likely to develop bacterial resistance with this drug, when administered without susceptibility confirmation.
Laboratory studies show that Augmentin – BID 500mg/125mg is potent against Staphylococcus Aureus, Escherichia Coli, Klebsiella, Enterococcus faecalis, Streptococcus pneumoniae, Neisseria gonorrhoeae, Streptococcus pyogenes, Staphylococcus epidermidis, Proteus mirabilis, etc…
As it can be deduced, Augmentin – BID 500mg/125mg is able to treat any infection caused by mentioned pathogenic agents. These include: lower respiratory tract infections, pyelonephritis, dermatological infections, otitis media, sinusitis, urinary tract infections.

Which threats are related to Augmentin – BID 500mg/125mg therapy?
Penicillin medications, including Augmentin – BID 500mg/125mg, might occasionally produce hypersensitive reaction. The allergic reaction manifests in severe form and can include anaphylactic shock. A profound inquiry about previous allergic responses should be performed before indicating this medication. Statistics show that such reaction is predominant (but not exclusive) in persons who have previously developed allergic reaction to cephalosporin group of drugs. In case that such history is present, patients should not take the risk.

Patients receiving antibiotics are prone to develop pseudo-membranous colitis. While intestinal flora is altered due to antibiotic activity, Clostridium difficile is probable to overgrow. This bacterium secretes certain toxins which are extremely harmful. Toxins affect the flora, leading to abnormal diarrhea and electrolyte imbalance. The phenomenon can develop to high degrees of severity, posing an eminent threat to patient’s life. Gastrointestinal colitis and diarrhea are syndromes which might predict the emerge of Clostridium Difficile-associated diarrhea. If the diagnose is confirmed, Augmentin – BID 500mg/125mg administration will de interrupted, and appropriate measures against the infection will be provided.

Augmentin – BID 500mg/125mg administration during pregnancy
Augmentin – BID 500mg/125mg antibacterial drug should be taken by pregnant women only in cases of major need for the mother, and when there are no safer alternatives available. The drug has not manifested toxic effects when observed in animal tests. However, findings based on animal studies cannot guarantee total safeness when Augmentin – BID 500mg/125mg is taken by pregnant women.

Possible side events
In terms of tolerability, Augmentin – BID 500mg/125mg has a rather positive profile. Watery stools are experienced by 7-9% of receivers. Nausea and vomiting affects less than 5% of users (3 and 1%, respectively). Skin affections (urticaria, for instance) are observed in 3% of patients.

Reviews

There are no reviews yet. Add a review